Navigation Links
Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
Date:4/23/2009

Conference Features Renowned Translational Cancer Researchers and Updates on Key Discoveries, Plus Panel Discussion with Academic and Industry Leaders

NEW YORK, April 23 /PRNewswire-USNewswire/ -- Internationally renowned physician-scientists will discuss the rapidly changing cancer research landscape in the US, plus important recent discoveries in translational cancer research, during the first Damon Runyon Cancer Research Foundation Clinical Investigator Symposium.

The April 27th event, to be held in partnership with the New York Academy of Sciences, includes a panel discussion on the evolving partnership between academia and industry in research and drug development.

Highlights:

  • Robert A. Weinberg, PhD, of the Whitehead Institute and MIT, will deliver the keynote address focusing on the molecular basis of malignancy. Dr. Weinberg is one of the nation's most distinguished cancer researchers, most widely known for his pioneering discovery of the first human oncogene (Ras).
  • Scott Hensley, award-winning healthcare writer and editor, will moderate a panel discussion titled "Moving from Discovery through Development - The Evolving Relationship between Academia and Industry." Panel participants include senior scientists from leading academic cancer centers and representatives from industry:
  • Jakob Dupont, MD, Medical Director, BioOncology, Genentech, Inc.;
  • Richard B. Gaynor, MD, VP, Cancer Research and Global Oncology, Eli Lilly and Co.;
  • John Mendelsohn, MD, President, M.D. Anderson Cancer Center;
  • Donald W. Rucker, MD, VP and Chief Medical Officer, Siemens Medical Solutions USA;
  • Charles L. Sawyers, MD, Chairman of Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center.
  • Damon Runyon Clinical Investigators, a select group of innovative physician-scientists funded through the Damon Runyon Clinical Investigator Award program, will discuss their groundbreaking translational research, covering a broad range of topics including the latest work in cancer prevention, biomarkers, cancer stem cells and immunotherapy.

Presenting Damon Runyon Clinical Investigators include:

  • Jeremy N. Rich, MD, Chairman, Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic - Cancer Stem Cells
  • Maura L. Gillison, MD, PhD, Professor of Medicine and Chair of Cancer Research, Ohio State University - HPV and Head and Neck Cancer
  • Joseph A. Califano, III, MD, Professor of Otolaryngology, Johns Hopkins University School of Medicine - Using Bodily Fluids for Early Detection of Cancers
  • Cassian Yee, MD, Associate Member, Clinical Research Program in Immunology, Fred Hutchinson Cancer Research Center - Adoptive T Cell Therapy

The symposium marks the 10th anniversary of the prestigious Damon Runyon Clinical Investigator Award, which addresses the critical demand for physicians capable of translating scientific discovery into new breakthroughs for cancer patients.

Media coverage of this event is encouraged.

    Contact:
    Catherine Bright
    Damon Runyon Cancer Research Foundation
    212.455.0506 or catherine.bright@damonrunyon.org

    Bill Silberg
    New York Academy of Sciences
    212.298.8646 or BSilberg@nyas.org

To see the event detail page, including agenda, speaker bios, scientific advisory committee and sign-up info, go to www.nyas.org/damonrunyon

Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation's mission is to find the most brilliant and promising scientists and provide them with funding to pursue innovative research that will eliminate cancer as a deadly disease. Our strategy is to:

  • Recruit the best and brightest early-career scientists into cancer research.
  • Accelerate the translation of scientific discoveries into new diagnostic tools and treatments.
  • Enable risk-taking on bold new ideas.

Eleven scientists supported by the Foundation have received the Nobel Prize. Since 1946, the Foundation has invested over $220 million and funded more than 3,200 scientists.

100% of all donations to the Foundation are used to support scientific research. Administrative and fundraising costs are paid from its Damon Runyon Broadway Tickets Service and endowment.

The Damon Runyon Clinical Investigator Award selects top early-career physician-scientists conducting patient-oriented cancer research and provides them with the resources and training essential to becoming leaders in this important field. Since 2000, the Foundation has committed more than $30 million to support 44 exceptional physician-scientists from across the United States.

For more information visit www.damonrunyon.org

New York Academy of Sciences:

Founded in 1817, the New York Academy of Sciences (NYAS) is an independent, nonprofit organization committed to advancing science, technology, and society worldwide. With about 24,000 members in 140 countries, NYAS is creating a global community of science for the benefit of humanity. NYAS' core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large.


'/>"/>
SOURCE Damon Runyon Cancer Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reminder: Volcano Corporation Schedules Conference Call, Webcast to Discuss Axsun Transaction
2. Physician Reminder: Importation is Illegal
3. Tax Season Reminder: Vehicle Donations Still Needed
4. Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting
5. Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
6. NIH grant to strengthen IU and Purdue program to educate physician-scientists
7. NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting
8. NYP/Columbia physician-scientists present at ASCO 44th annual meeting
9. BWF awards $11.2 million to support physician-scientists
10. NewYork-Presbyterian/Columbia physician-scientists present at ACCs 57th Annual Scientific Session
11. AmericaSpeakOn.org Launches Discussion on Health Care Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for ... Center in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... that their Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' ... The Staffing 100 honors those who have made notable contributions to the staffing ...
(Date:2/17/2017)... CO (PRWEB) , ... February 17, 2017 , ... Top ... annual International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, ... Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Inc. (NYSE: DVA ) today announced results for ... Net income attributable to DaVita Inc. for the quarter ... $0.80 per share and $880 million, or $4.29 per share, ... Inc. for the quarter and year ended December 31, 2016, ... $0.98 per share, and $789 million, or $3.85 per share, ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology: